Article Text

Download PDFPDF

TP014/#1529 Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I-II endometrial cancer (KGOG2029/SELYE)
Free
  1. Jeong-Yeol Park1,
  2. Eunhyang Park2 and
  3. Sang Wun Kim3
  1. 1University of Ulsan College of Medicine, Asan Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of
  2. 2Yonsei University College of Medicine, Pathology, Seoul, Korea, Republic of
  3. 3Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of

Abstract

Objectives Sentinel lymph node (SLN) mapping has been suggested as an alternative surgical technique to lymph node dissection (LND) for early-stage endometrial cancer. However, the survival outcomes of SLN mapping compared with LND have not been established via prospective randomized controlled trials. The primary endpoint of the Gynecologic Oncology Group 2029 trial (KGOG2029/SELYE) is the 3-year disease-free survival (DFS) of SLN mapping versus LND. The secondary endpoints are 3-year overall survival (OS), 5-year DFS, 5-year OS, pattern of recurrence, immediate surgical outcomes, SLN mapping success rate, postoperative lymph-related complications, postoperative QOL, and the cost-effectiveness of SLN mapping versus LND.

Methods The KGOG2029/SEYLE trial is a multi-center, single-blind, randomized controlled trial which has been designed to determine the prognostic value of SLN mapping alone compared with conventional lymphadenectomy for patients with clinical stage I-II endometrial cancer of any histologic type and any histologic grade. Study patients will be classified into low/intermediate-risk and high-risk groups according to the risk of lymph node metastasis. A low/intermediate-risk group will undergo pelvic SLN mapping in SLN group and will undergo pelvic lymph node dissection in LND group. A high-risk group will undergo a 2-step SLN mapping procedure consisting of para-aortic SLN mapping (first step) and pelvic SLN mapping (second step) in SLN group and will undergo pelvic and para-aortic lymph node dissection in LND group. Eighty-one of planned 810 patients have been enrolled at the time of submission.

Results There are no available results at the time of submission.

Conclusions There are no available conclusions at the time of submission.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.